This stock has huge potential on the upside ($40 per share), and relatively low risk on the downside ($.75). They have financial support from large succesful organizations such as genetech and they have many avenues and ways to attempt to end various forms of cancer. This is currently the best attempt we have at ending certain types of cancer.

The bright prospects Curis (CRIS) has have been ignored by the major movers on Wall Street. CRIS has 3 drugs in Phase 3 trials. In two of those trials they are partnering with Genetech, which is running the trials (and is now owned by Roche). One of these trials is a 100 person pivotal trial to show the long term effectiveness of their drug designed to cure basal cell carcinoma (BCC). This same drug had a very high overall response rate in a smaller Phase 2 BCC trial . Right now this same compound is being tested in many Phase 2 trials (to trest other cancers) sponsored by the National Cancer Institute and other prestigious health providers. I am a owner of CRIS.